HOUT-03. SCREENING FOR MOOD DISTURBANCE IN LONG-TERM CENTRAL NERVOUS SYSTEM (CNS) TUMOR SURVIVORS USING PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): A NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) REPORT

Abstract BACKGROUND Survivorship is an important area of cancer care and research. There are limited studies exploring the experience of long term survivors of CNS tumors. A recent review of quality of life in adults with CNS tumors underscored the need for studies exploring patient outcomes, includ...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Va.), 2018-11, Vol.20 (suppl_6), p.vi113-vi113
Main Authors: Ruiz, María Fletcher, Vera, Elizabeth, Acquaye, Alvina, Boris, Lisa, Brown, Miranda, Crandon, Sonja, Garren, Nancy, Ji, Ming, Levine, Jason, Reyes, Jennifer, Siegel, Christine, Wu, Jing, Gilbert, Mark, Armstrong, Terri
Format: Article
Language:English
Subjects:
Abstracts
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page vi113
container_issue suppl_6
container_start_page vi113
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 20
creator Ruiz, María Fletcher
Vera, Elizabeth
Acquaye, Alvina
Boris, Lisa
Brown, Miranda
Crandon, Sonja
Garren, Nancy
Ji, Ming
Levine, Jason
Reyes, Jennifer
Siegel, Christine
Wu, Jing
Gilbert, Mark
Armstrong, Terri
description Abstract BACKGROUND Survivorship is an important area of cancer care and research. There are limited studies exploring the experience of long term survivors of CNS tumors. A recent review of quality of life in adults with CNS tumors underscored the need for studies exploring patient outcomes, including mood disturbance. This report explores mood disturbance in CNS tumor patients living greater than 5 years from diagnosis. METHODS Patients enrolled on the NOB-NHS were included. PROMIS depression/anxiety measures were completed at study entry. T-scores >60 were considered significant. Independent sample t-tests, chi-square and Fishers Exact tests were used to identify associations with mood disturbance. Significance level was set at 0.05. RESULTS 132 patients, primarily white (84%), males (58%), with median age 49 (22–81), were included with 59% having low grade tumors; oligodendroglioma (19%) was the most common diagnosis, 30% underwent gross total resection, 33% had had a recurrence and 27% had a poor KPS (80). Five percent were on corticosteroids and 20% on psychotropic medications. Overall, 14% and 18% reported significant depression and anxiety respectively, with 10% reporting both. More non-white [29% vs 11%; X2 (1) = 4.4, p
doi_str_mv 10.1093/neuonc/noy148.471
format article
fullrecord <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6216981</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noy148.471</oup_id><sourcerecordid>10.1093/neuonc/noy148.471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1771-3c99bc927492c79bfe2d332a646cccc85159ced3d5a1f08efcfdec10c335ef7d3</originalsourceid><addsrcrecordid>eNqNkV9r2zAUxU3ZoF23D7C3-9jCnFpW_G8PA8dRY0MsBckO5Mk4srxltHawl0E_8r7FbupS6Fv1IsG953cOOpb1lTgz4kT0rjOnvtN3Xf9E5uFsHpAL64p4LrW90Pc_PL9dO_RIcGl9GsffjuMSzydX1r9UlIXt0BmoRDLGM76CeyEhF2IJy0wVpVzEPGGQcVgLvrILJnNIGC9kvAbO5FaUCtROFSyHm4SrWyjKHAGqlNtsK6SCUp2hm7jIUAWSbYQs2BLQNxE5U5CzGJdZfp5mHM1zXBX8FbqRIs_U7XeI0a-UwhY8EWux2sFCYrQUeIwpMU2KcYXcAYZe7uCGi4XNUww0WX62Prb1w2i-vNzXVnnPiiS1EZUl8drWJAiITXUU7XXkBvPI1UG0b43bUOrW_tzXePALvUibhjZeTVonNK1uG6OJoyn1TBs09Nr6MXGPp_2jabTp_gz1Q3UcDo_18FT19aF6O-kOv6qf_d_Kd4kfhQQBZALooR_HwbSvWuJU57KrqexqKrvCslHzbdL0p-M71v8DO86h8Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>HOUT-03. SCREENING FOR MOOD DISTURBANCE IN LONG-TERM CENTRAL NERVOUS SYSTEM (CNS) TUMOR SURVIVORS USING PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): A NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) REPORT</title><source>Oxford Journals Online</source><source>PubMed Central</source><creator>Ruiz, María Fletcher ; Vera, Elizabeth ; Acquaye, Alvina ; Boris, Lisa ; Brown, Miranda ; Crandon, Sonja ; Garren, Nancy ; Ji, Ming ; Levine, Jason ; Reyes, Jennifer ; Siegel, Christine ; Wu, Jing ; Gilbert, Mark ; Armstrong, Terri</creator><creatorcontrib>Ruiz, María Fletcher ; Vera, Elizabeth ; Acquaye, Alvina ; Boris, Lisa ; Brown, Miranda ; Crandon, Sonja ; Garren, Nancy ; Ji, Ming ; Levine, Jason ; Reyes, Jennifer ; Siegel, Christine ; Wu, Jing ; Gilbert, Mark ; Armstrong, Terri</creatorcontrib><description>Abstract BACKGROUND Survivorship is an important area of cancer care and research. There are limited studies exploring the experience of long term survivors of CNS tumors. A recent review of quality of life in adults with CNS tumors underscored the need for studies exploring patient outcomes, including mood disturbance. This report explores mood disturbance in CNS tumor patients living greater than 5 years from diagnosis. METHODS Patients enrolled on the NOB-NHS were included. PROMIS depression/anxiety measures were completed at study entry. T-scores &gt;60 were considered significant. Independent sample t-tests, chi-square and Fishers Exact tests were used to identify associations with mood disturbance. Significance level was set at 0.05. RESULTS 132 patients, primarily white (84%), males (58%), with median age 49 (22–81), were included with 59% having low grade tumors; oligodendroglioma (19%) was the most common diagnosis, 30% underwent gross total resection, 33% had had a recurrence and 27% had a poor KPS (80). Five percent were on corticosteroids and 20% on psychotropic medications. Overall, 14% and 18% reported significant depression and anxiety respectively, with 10% reporting both. More non-white [29% vs 11%; X2 (1) = 4.4, p&lt;0.04] reported significant depressive symptoms, as did those with poor KPS [25% vs. 10%; X2 (1) = 4.2, p&lt;0.04] and those on psychotropic medications [27% vs 11%; X2 (1) = 4.5, p&lt;0.04]. Anxiety was only associated with the use of psychotropic medications [38% vs. 13%; X2 (1) = 9.3, p&lt;0.01]. CONCLUSION Symptoms of depression and anxiety occurred in 20% of long-term brain tumor survivors on screening. Depressive symptoms were associated with race, lower KPS, and use of psychotropic medications. Additionally, use of psychotropic medications was associated with anxiety. Assessment of depression and anxiety as part of survivorship care is warranted. Future studies exploring phenotypes at risk and targeted interventions are needed to mitigate these symptoms.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noy148.471</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Abstracts</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi113-vi113</ispartof><rights>The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216981/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216981/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Ruiz, María Fletcher</creatorcontrib><creatorcontrib>Vera, Elizabeth</creatorcontrib><creatorcontrib>Acquaye, Alvina</creatorcontrib><creatorcontrib>Boris, Lisa</creatorcontrib><creatorcontrib>Brown, Miranda</creatorcontrib><creatorcontrib>Crandon, Sonja</creatorcontrib><creatorcontrib>Garren, Nancy</creatorcontrib><creatorcontrib>Ji, Ming</creatorcontrib><creatorcontrib>Levine, Jason</creatorcontrib><creatorcontrib>Reyes, Jennifer</creatorcontrib><creatorcontrib>Siegel, Christine</creatorcontrib><creatorcontrib>Wu, Jing</creatorcontrib><creatorcontrib>Gilbert, Mark</creatorcontrib><creatorcontrib>Armstrong, Terri</creatorcontrib><title>HOUT-03. SCREENING FOR MOOD DISTURBANCE IN LONG-TERM CENTRAL NERVOUS SYSTEM (CNS) TUMOR SURVIVORS USING PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): A NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) REPORT</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract BACKGROUND Survivorship is an important area of cancer care and research. There are limited studies exploring the experience of long term survivors of CNS tumors. A recent review of quality of life in adults with CNS tumors underscored the need for studies exploring patient outcomes, including mood disturbance. This report explores mood disturbance in CNS tumor patients living greater than 5 years from diagnosis. METHODS Patients enrolled on the NOB-NHS were included. PROMIS depression/anxiety measures were completed at study entry. T-scores &gt;60 were considered significant. Independent sample t-tests, chi-square and Fishers Exact tests were used to identify associations with mood disturbance. Significance level was set at 0.05. RESULTS 132 patients, primarily white (84%), males (58%), with median age 49 (22–81), were included with 59% having low grade tumors; oligodendroglioma (19%) was the most common diagnosis, 30% underwent gross total resection, 33% had had a recurrence and 27% had a poor KPS (80). Five percent were on corticosteroids and 20% on psychotropic medications. Overall, 14% and 18% reported significant depression and anxiety respectively, with 10% reporting both. More non-white [29% vs 11%; X2 (1) = 4.4, p&lt;0.04] reported significant depressive symptoms, as did those with poor KPS [25% vs. 10%; X2 (1) = 4.2, p&lt;0.04] and those on psychotropic medications [27% vs 11%; X2 (1) = 4.5, p&lt;0.04]. Anxiety was only associated with the use of psychotropic medications [38% vs. 13%; X2 (1) = 9.3, p&lt;0.01]. CONCLUSION Symptoms of depression and anxiety occurred in 20% of long-term brain tumor survivors on screening. Depressive symptoms were associated with race, lower KPS, and use of psychotropic medications. Additionally, use of psychotropic medications was associated with anxiety. Assessment of depression and anxiety as part of survivorship care is warranted. Future studies exploring phenotypes at risk and targeted interventions are needed to mitigate these symptoms.</description><subject>Abstracts</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqNkV9r2zAUxU3ZoF23D7C3-9jCnFpW_G8PA8dRY0MsBckO5Mk4srxltHawl0E_8r7FbupS6Fv1IsG953cOOpb1lTgz4kT0rjOnvtN3Xf9E5uFsHpAL64p4LrW90Pc_PL9dO_RIcGl9GsffjuMSzydX1r9UlIXt0BmoRDLGM76CeyEhF2IJy0wVpVzEPGGQcVgLvrILJnNIGC9kvAbO5FaUCtROFSyHm4SrWyjKHAGqlNtsK6SCUp2hm7jIUAWSbYQs2BLQNxE5U5CzGJdZfp5mHM1zXBX8FbqRIs_U7XeI0a-UwhY8EWux2sFCYrQUeIwpMU2KcYXcAYZe7uCGi4XNUww0WX62Prb1w2i-vNzXVnnPiiS1EZUl8drWJAiITXUU7XXkBvPI1UG0b43bUOrW_tzXePALvUibhjZeTVonNK1uG6OJoyn1TBs09Nr6MXGPp_2jabTp_gz1Q3UcDo_18FT19aF6O-kOv6qf_d_Kd4kfhQQBZALooR_HwbSvWuJU57KrqexqKrvCslHzbdL0p-M71v8DO86h8Q</recordid><startdate>20181105</startdate><enddate>20181105</enddate><creator>Ruiz, María Fletcher</creator><creator>Vera, Elizabeth</creator><creator>Acquaye, Alvina</creator><creator>Boris, Lisa</creator><creator>Brown, Miranda</creator><creator>Crandon, Sonja</creator><creator>Garren, Nancy</creator><creator>Ji, Ming</creator><creator>Levine, Jason</creator><creator>Reyes, Jennifer</creator><creator>Siegel, Christine</creator><creator>Wu, Jing</creator><creator>Gilbert, Mark</creator><creator>Armstrong, Terri</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20181105</creationdate><title>HOUT-03. SCREENING FOR MOOD DISTURBANCE IN LONG-TERM CENTRAL NERVOUS SYSTEM (CNS) TUMOR SURVIVORS USING PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): A NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) REPORT</title><author>Ruiz, María Fletcher ; Vera, Elizabeth ; Acquaye, Alvina ; Boris, Lisa ; Brown, Miranda ; Crandon, Sonja ; Garren, Nancy ; Ji, Ming ; Levine, Jason ; Reyes, Jennifer ; Siegel, Christine ; Wu, Jing ; Gilbert, Mark ; Armstrong, Terri</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1771-3c99bc927492c79bfe2d332a646cccc85159ced3d5a1f08efcfdec10c335ef7d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Abstracts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ruiz, María Fletcher</creatorcontrib><creatorcontrib>Vera, Elizabeth</creatorcontrib><creatorcontrib>Acquaye, Alvina</creatorcontrib><creatorcontrib>Boris, Lisa</creatorcontrib><creatorcontrib>Brown, Miranda</creatorcontrib><creatorcontrib>Crandon, Sonja</creatorcontrib><creatorcontrib>Garren, Nancy</creatorcontrib><creatorcontrib>Ji, Ming</creatorcontrib><creatorcontrib>Levine, Jason</creatorcontrib><creatorcontrib>Reyes, Jennifer</creatorcontrib><creatorcontrib>Siegel, Christine</creatorcontrib><creatorcontrib>Wu, Jing</creatorcontrib><creatorcontrib>Gilbert, Mark</creatorcontrib><creatorcontrib>Armstrong, Terri</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ruiz, María Fletcher</au><au>Vera, Elizabeth</au><au>Acquaye, Alvina</au><au>Boris, Lisa</au><au>Brown, Miranda</au><au>Crandon, Sonja</au><au>Garren, Nancy</au><au>Ji, Ming</au><au>Levine, Jason</au><au>Reyes, Jennifer</au><au>Siegel, Christine</au><au>Wu, Jing</au><au>Gilbert, Mark</au><au>Armstrong, Terri</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HOUT-03. SCREENING FOR MOOD DISTURBANCE IN LONG-TERM CENTRAL NERVOUS SYSTEM (CNS) TUMOR SURVIVORS USING PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): A NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) REPORT</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2018-11-05</date><risdate>2018</risdate><volume>20</volume><issue>suppl_6</issue><spage>vi113</spage><epage>vi113</epage><pages>vi113-vi113</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract BACKGROUND Survivorship is an important area of cancer care and research. There are limited studies exploring the experience of long term survivors of CNS tumors. A recent review of quality of life in adults with CNS tumors underscored the need for studies exploring patient outcomes, including mood disturbance. This report explores mood disturbance in CNS tumor patients living greater than 5 years from diagnosis. METHODS Patients enrolled on the NOB-NHS were included. PROMIS depression/anxiety measures were completed at study entry. T-scores &gt;60 were considered significant. Independent sample t-tests, chi-square and Fishers Exact tests were used to identify associations with mood disturbance. Significance level was set at 0.05. RESULTS 132 patients, primarily white (84%), males (58%), with median age 49 (22–81), were included with 59% having low grade tumors; oligodendroglioma (19%) was the most common diagnosis, 30% underwent gross total resection, 33% had had a recurrence and 27% had a poor KPS (80). Five percent were on corticosteroids and 20% on psychotropic medications. Overall, 14% and 18% reported significant depression and anxiety respectively, with 10% reporting both. More non-white [29% vs 11%; X2 (1) = 4.4, p&lt;0.04] reported significant depressive symptoms, as did those with poor KPS [25% vs. 10%; X2 (1) = 4.2, p&lt;0.04] and those on psychotropic medications [27% vs 11%; X2 (1) = 4.5, p&lt;0.04]. Anxiety was only associated with the use of psychotropic medications [38% vs. 13%; X2 (1) = 9.3, p&lt;0.01]. CONCLUSION Symptoms of depression and anxiety occurred in 20% of long-term brain tumor survivors on screening. Depressive symptoms were associated with race, lower KPS, and use of psychotropic medications. Additionally, use of psychotropic medications was associated with anxiety. Assessment of depression and anxiety as part of survivorship care is warranted. Future studies exploring phenotypes at risk and targeted interventions are needed to mitigate these symptoms.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noy148.471</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi113-vi113
issn 1522-8517
1523-5866
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6216981
source Oxford Journals Online; PubMed Central
subjects Abstracts
title HOUT-03. SCREENING FOR MOOD DISTURBANCE IN LONG-TERM CENTRAL NERVOUS SYSTEM (CNS) TUMOR SURVIVORS USING PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): A NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) REPORT
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A22%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HOUT-03.%20SCREENING%20FOR%20MOOD%20DISTURBANCE%20IN%20LONG-TERM%20CENTRAL%20NERVOUS%20SYSTEM%20(CNS)%20TUMOR%20SURVIVORS%20USING%20PATIENT%20REPORTED%20OUTCOMES%20MEASUREMENT%20INFORMATION%20SYSTEM%20(PROMIS):%20A%20NEURO-ONCOLOGY%20BRANCH%20NATURAL%20HISTORY%20STUDY%20(NOB-NHS)%20REPORT&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Ruiz,%20Mar%C3%ADa%20Fletcher&rft.date=2018-11-05&rft.volume=20&rft.issue=suppl_6&rft.spage=vi113&rft.epage=vi113&rft.pages=vi113-vi113&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noy148.471&rft_dat=%3Coup_pubme%3E10.1093/neuonc/noy148.471%3C/oup_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1771-3c99bc927492c79bfe2d332a646cccc85159ced3d5a1f08efcfdec10c335ef7d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noy148.471&rfr_iscdi=true